Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity
Year: 2025
Type: article
Language: en
Topic: Cancer, Hypoxia, and Metabolism
Authors and affiliations:
raw_author_name: Jian Gu
raw_affiliation_strings: Jiangsu Key Laboratory of Organ Transplantation and Transplant Immunology and Hepatobiliary Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: gujian@njmu.edu.cn
raw_author_name: Yu Li
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Qiuyang Chen
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Ziyan Song
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Qufei Qian
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Yuan Liang
raw_affiliation_strings: School of Biological Science & Medical Engineering, Southeast University, Nanjing, China
raw_author_name: Tianning Huang
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Lei Qiao
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Xiangyu Li
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Miao Yu
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Mu Liu
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Jinren Zhou
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Qing Shao
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Xiaozhang Xu
raw_affiliation_strings: Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
raw_author_name: Robert Zeiser
raw_affiliation_strings: Faculty of Medicine, Clinic for Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany
raw_author_name: Ling Lu
raw_affiliation_strings: Jiangsu Key Laboratory of Organ Transplantation and Transplant Immunology and Hepatobiliary Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: lvling@njmu.edu.cn